TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Ulcerative Colitis
Advertisement
Alvotech Reports Positive PK Data for Entyvio Biosimilar
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
FDA Clears MRM Health’s Phase 2b Microbiome Trial in UC
GHENT, Belgium | January 9, 2026 — MRM Health announced that the U.S. Food and Drug Administration (FDA) has...
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
TREMFYA® Receives FDA Approval for Subcutaneous Induction in UC
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
Advertisement
